New Company for New Therapeutics for Prostate Cancer, New therapeutic approches for prostate cancer door Jack Schalken
•Download as PPT, PDF•
1 like•368 views
Prostate cancer diagnoses and deaths remain high, with unmet needs in early detection, locally advanced and metastatic treatment. A new therapeutic approach is being developed through the PRO-NET Consortium to address these needs using a multi-marker diagnostic and combination therapy targeting multiple pathways. Forming an independent company is seen as essential to securing intellectual property and pursuing venture capital funding to support clinical trials and market entry, with forecasts of substantial revenues and market share within 5 years if successful.
Report
Share
Report
Share
![Prostate Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
NY Prostate Cancer Conference - C. Foster - Session 1: From cancer biomarkers...
NY Prostate Cancer Conference - C. Foster - Session 1: From cancer biomarkers...European School of Oncology
This document discusses using biomarkers to stratify cancer treatment approaches. It describes prostate cancer biomarker studies identifying markers like Hsp-27, PKC-ζ, and AGR-2 that can predict cancer behavior and clinical outcomes. Isoform-specific PKC-ζ inhibitors were developed and shown to inhibit prostate cancer cell growth in vitro, demonstrating how biomarkers can be used to identify therapeutic targets. The document advocates stratifying cancer patient management based on biomarkers from initial diagnosis through to targeted treatment selection and monitoring.NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...European School of Oncology
The document summarizes research on active surveillance for prostate cancer. It discusses definitions of clinically significant prostate cancer, criteria for active surveillance candidacy, biomarkers like PSA kinetics and PCA3, and outcomes of patients on surveillance like cancer-specific survival rates and rates of remaining free from intervention. It concludes that active surveillance appears safe in the intermediate term but challenges remain in identifying higher risk disease and validating triggers for intervention.Lexalytics Text Analytics Workshop: Perfect Text Analytics
This document summarizes and promotes the text analytics capabilities of Perfect Text Analytics. It discusses how Perfect is fast, usable, consistent, provides new knowledge, is inclusive of all text, and is trainable. Customer use cases are presented in reputation management, politics, market intelligence, hospitality, financial services, pharma, and opinion mining. The document outlines planned enhancements over the next year, including sarcasm detection, foreign language support, and more customizable tools. Overall, it argues that text analytics can provide valuable insights across many industries when combined with business logic.
Utilidad del PCA3 en el diagnóstico del cáncer de próstata.
El cáncer de próstata es uno de los tumores mas frecuentes en los países desarrollados. Desde hace 25 años el PSA ha sido de gran utilidad para identificar pacientes con riesgo elevado de presentar cáncer de próstata para ser sometidos a biopsia. Sin embargo, el valor predictivo positivo del PSA es bajo (25%), lo mismo que la sensibilidad y especificidad. Solo uno de cada 4 casos con PSA elevado mostrarán cáncer de próstata en la biopsia lo que lo que significa que se están realizando demasiadas biopsia innecesarias lo que no solamente incrementa muchos los costes sino que además los pacientes son sometidos a procedimientos invasivos con incidencia de complicaciones (sangrado, infección, etc). Desde hace pocos años se ha introducido el PCA3 en el diagnóstico del cáncer de próstata con la finalidad de reducir el número de biopsias innecesarias que se realizan. Desde 2012 la Food and Drug Administration de USA han autorizado el PCA3 en el diagnóstico del cáncer de próstata. Presentamos nuestra experiencia en la utilización de PCA3 en el diagnóstico de cáncer de próstata. Realizamos biopsia de próstata en los pacientes con PCA3 de 35 o superior y observamos que 50% de los mismos presentaron cáncer en la primera o segunda biopsia. Por el contrario, en los casos con PCA3 menor de 35, solo 5% de los casos presentaron cáncer de próstata durante el seguimiento.
2013-11-14 NVKCL symposium, Utrecht
The document discusses biomarkers in oncology from cells to systems. It notes that while many biomarkers are discovered, few progress beyond initial publication to clinical validation and diagnostic tests. Reasons for this innovation gap include a lack of integrated biomarker research and development pipelines and challenges in organizing multi-lab validation studies. The talk emphasizes embracing novel omics technologies, considering tumor cells as part of a biological system, and focusing on biomarker validation to address this gap. It provides examples of using mRNA expression profiling and systems-level approaches to stratify and characterize tumors.
NGNM Company Overview Presentation Aug 2013
- NeoGenomics is a pure-play cancer genetics testing company that has experienced fast revenue and test volume growth through expanding its test menu and increasing sales force productivity. Its "tech-only" business model focuses on partnerships with oncologists and hospitals to provide genetic testing services.
- The company has consistently grown its annual revenue and tests performed historically through new test innovations, a growing sales force, and greater productivity. It is targeting further market share gains and operating leverage to accelerate cash flow and earnings growth.
NGNM Company Overview Presentation July 2013
NeoGenomics provides cancer genetic testing services to oncologists, pathologists, and hospitals. It has experienced strong and consistent growth in revenue and tests performed annually through expanding its test menu, increasing sales force productivity, and gaining market share. The company aims to continue its growth by launching new tests, pursuing partnerships and acquisitions, and capitalizing on the large and growing market for cancer genetic testing fueled by an aging population and advancements in targeted therapies.
Cancer Genetics Earnings Call
Cancer Genetics reported on its Q4 and full year 2016 earnings. Key highlights included 50% revenue growth in 2016 to $27 million, driven by increases in biopharma, clinical, and discovery services. The company realized operational efficiencies through integration of acquisitions, reducing expenses. However, the company reported a net loss of $15.8 million for 2016. In Q4 2016, revenue increased 32% to $7.2 million while expenses decreased, though the company reported a net loss of $2.8 million. Additionally, Cancer Genetics completed a $12 million debt refinancing to repay existing debt and access additional capital.
Recommended
NY Prostate Cancer Conference - C. Foster - Session 1: From cancer biomarkers...
NY Prostate Cancer Conference - C. Foster - Session 1: From cancer biomarkers...European School of Oncology
This document discusses using biomarkers to stratify cancer treatment approaches. It describes prostate cancer biomarker studies identifying markers like Hsp-27, PKC-ζ, and AGR-2 that can predict cancer behavior and clinical outcomes. Isoform-specific PKC-ζ inhibitors were developed and shown to inhibit prostate cancer cell growth in vitro, demonstrating how biomarkers can be used to identify therapeutic targets. The document advocates stratifying cancer patient management based on biomarkers from initial diagnosis through to targeted treatment selection and monitoring.NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...European School of Oncology
The document summarizes research on active surveillance for prostate cancer. It discusses definitions of clinically significant prostate cancer, criteria for active surveillance candidacy, biomarkers like PSA kinetics and PCA3, and outcomes of patients on surveillance like cancer-specific survival rates and rates of remaining free from intervention. It concludes that active surveillance appears safe in the intermediate term but challenges remain in identifying higher risk disease and validating triggers for intervention.Lexalytics Text Analytics Workshop: Perfect Text Analytics
This document summarizes and promotes the text analytics capabilities of Perfect Text Analytics. It discusses how Perfect is fast, usable, consistent, provides new knowledge, is inclusive of all text, and is trainable. Customer use cases are presented in reputation management, politics, market intelligence, hospitality, financial services, pharma, and opinion mining. The document outlines planned enhancements over the next year, including sarcasm detection, foreign language support, and more customizable tools. Overall, it argues that text analytics can provide valuable insights across many industries when combined with business logic.
Utilidad del PCA3 en el diagnóstico del cáncer de próstata.
El cáncer de próstata es uno de los tumores mas frecuentes en los países desarrollados. Desde hace 25 años el PSA ha sido de gran utilidad para identificar pacientes con riesgo elevado de presentar cáncer de próstata para ser sometidos a biopsia. Sin embargo, el valor predictivo positivo del PSA es bajo (25%), lo mismo que la sensibilidad y especificidad. Solo uno de cada 4 casos con PSA elevado mostrarán cáncer de próstata en la biopsia lo que lo que significa que se están realizando demasiadas biopsia innecesarias lo que no solamente incrementa muchos los costes sino que además los pacientes son sometidos a procedimientos invasivos con incidencia de complicaciones (sangrado, infección, etc). Desde hace pocos años se ha introducido el PCA3 en el diagnóstico del cáncer de próstata con la finalidad de reducir el número de biopsias innecesarias que se realizan. Desde 2012 la Food and Drug Administration de USA han autorizado el PCA3 en el diagnóstico del cáncer de próstata. Presentamos nuestra experiencia en la utilización de PCA3 en el diagnóstico de cáncer de próstata. Realizamos biopsia de próstata en los pacientes con PCA3 de 35 o superior y observamos que 50% de los mismos presentaron cáncer en la primera o segunda biopsia. Por el contrario, en los casos con PCA3 menor de 35, solo 5% de los casos presentaron cáncer de próstata durante el seguimiento.
2013-11-14 NVKCL symposium, Utrecht
The document discusses biomarkers in oncology from cells to systems. It notes that while many biomarkers are discovered, few progress beyond initial publication to clinical validation and diagnostic tests. Reasons for this innovation gap include a lack of integrated biomarker research and development pipelines and challenges in organizing multi-lab validation studies. The talk emphasizes embracing novel omics technologies, considering tumor cells as part of a biological system, and focusing on biomarker validation to address this gap. It provides examples of using mRNA expression profiling and systems-level approaches to stratify and characterize tumors.
NGNM Company Overview Presentation Aug 2013
- NeoGenomics is a pure-play cancer genetics testing company that has experienced fast revenue and test volume growth through expanding its test menu and increasing sales force productivity. Its "tech-only" business model focuses on partnerships with oncologists and hospitals to provide genetic testing services.
- The company has consistently grown its annual revenue and tests performed historically through new test innovations, a growing sales force, and greater productivity. It is targeting further market share gains and operating leverage to accelerate cash flow and earnings growth.
NGNM Company Overview Presentation July 2013
NeoGenomics provides cancer genetic testing services to oncologists, pathologists, and hospitals. It has experienced strong and consistent growth in revenue and tests performed annually through expanding its test menu, increasing sales force productivity, and gaining market share. The company aims to continue its growth by launching new tests, pursuing partnerships and acquisitions, and capitalizing on the large and growing market for cancer genetic testing fueled by an aging population and advancements in targeted therapies.
Cancer Genetics Earnings Call
Cancer Genetics reported on its Q4 and full year 2016 earnings. Key highlights included 50% revenue growth in 2016 to $27 million, driven by increases in biopharma, clinical, and discovery services. The company realized operational efficiencies through integration of acquisitions, reducing expenses. However, the company reported a net loss of $15.8 million for 2016. In Q4 2016, revenue increased 32% to $7.2 million while expenses decreased, though the company reported a net loss of $2.8 million. Additionally, Cancer Genetics completed a $12 million debt refinancing to repay existing debt and access additional capital.
SCIE Investor Presentation January 2017
This document discusses SpectraScience's optical biopsy technology platform and commercialization plans. The technology uses light to provide faster, non-invasive cancer detection compared to physical biopsies. Clinical studies show the technology exceeds accuracy criteria for detecting colon cancer. The company plans to commercialize the technology first in Europe, where distribution agreements are in place, to take advantage of single-payer healthcare systems and proven cost savings. Future indications for bladder, esophageal, and other cancers are also discussed.
2015 Investor Conference - Baxalta
The document outlines the strategic vision and priorities of Baxalta Incorporated, a $6 billion global biopharmaceutical company. It discusses plans to build three growing businesses in hematology, immunology, and oncology focused on orphan diseases. Baxalta aims to drive 6-8% annual sales growth through 20 new product launches by 2020, expanding its oncology business to $500 million plus in sales. The presentation highlights Baxalta's leadership team, global operations, robust pipeline, and financial outlook targeting high and sustainable margins through 2020.
2016 11 21 neo company overview presentation
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion that is growing due to cancer prevalence increasing with an aging population and more cancer tests through precision medicine.
- Recent financial performance shows year-over-year revenue growth of 142% and adjusted EBITDA growth of 224% for the first three quarters of 2016, which includes the effects of the Clarient acquisition.
Dendreon Strategic Analysis
Dendreon Corporation is developing novel immunotherapies to treat cancer. It has one product, Provenge, approved for late-stage prostate cancer which works by re-engaging the immune system. While showing promise, Provenge faces challenges of high costs, lengthy approval delays, and lawsuits seeking earlier access. Dendreon needs to diversify its pipeline and pursue financing to support clinical trials and market expansion.
Final_Medtronic+plc+ppt
Medtronic is a global leader in medical technology, services, and solutions, with $28.8 billion in annual revenue. It manufactures and markets device-based medical therapies for cardiac and vascular disease, spinal and orthopedic conditions, diabetes, and other chronic diseases. Some key points:
- Medtronic acquired Covidien in 2015 for $50 billion to expand its product portfolio and global reach. However, expenses increased greatly following the acquisition.
- Analysts have a average target price of $91.50 per share, citing Medtronic's leading position and innovation potential, though also noting increasing competition and pricing pressure.
- Using a DCF model, the analyst values Med
Dendreon Presentation
Dendreon Corporation is a biotechnology company focused on developing immunotherapies to treat cancer. It currently has one product, Provenge, approved for treating advanced prostate cancer. Provenge harnesses the power of the immune system by using a patient's own immune cells to fight cancer cells. Clinical trials showed Provenge increased survival rates by 22% in treated patients compared to the control group. However, Dendreon faces challenges of gaining FDA approval for additional indications and managing costs of manufacturing and distributing its complex cellular immunotherapy.
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
This document summarizes the 2015 annual meeting of Valeant Pharmaceuticals International, Inc. held on May 19, 2015 in Laval, Quebec, Canada. It introduces the board of directors and executive management in attendance. It reports that all proposed resolutions, including electing directors and ratifying the auditor, received over 90% shareholder approval. The document provides an overview of Valeant's business model, product portfolio, acquisition and R&D strategies, and highlights key pipeline and launch products. It concludes by emphasizing Valeant's track record of strong financial performance and shareholder returns.
NeoGenomics Laboratory Company Overview Presentation 01/20/2014
NeoGenomics Laboratory Company Overview Presentation 01/20/2014NeoGenomics Laboratory | Cancer Diagnostics
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experienceCrb Bio Ii Summary Nov2010 Eng
This document introduces a new €60 million venture capital fund called CRB Bio II that will invest in early-stage biotech companies. It will be managed by CRB Inverbío, a new venture capital firm created by the founding partners of Cross Road Biotech, a Spanish VC firm with experience investing in 11 biotech companies. The fund aims to generate high returns by leveraging the management team's expertise and network in the biotech industry in Spain.
NeoGenomics Laboratory Company Overview Presentation 01/09/2014
NeoGenomics Laboratory Company Overview Presentation 01/09/2014NeoGenomics Laboratory | Cancer Diagnostics
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experienceNeoGenomics Laboratory Company Overview Presentation 02/19/2014
NeoGenomics Laboratory Company Overview Presentation 02/19/2014NeoGenomics Laboratory | Cancer Diagnostics
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experienceCancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...NeoGenomics Laboratory | Cancer Diagnostics
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experienceNeoGenomics Company Overview 2.22.16
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
2014 03 11 neo company overview presentation
The presentation provides an overview of NeoGenomics, a cancer genetic testing company. It highlights the company's consistent historical growth in tests performed and revenue. The management team has significant experience in large cap clinical laboratories. The company aims to continue expanding its test menu and market share through new product development and partnerships within the fast-growing cancer genetic testing industry.
NeoGenomics Laboratory Company Overview 2014-03-11
This presentation provides an overview of NeoGenomics, a cancer genetic testing company. Key points include:
- NeoGenomics has experienced consistent historical growth in the number of cancer tests performed and annual revenue.
- The company focuses on fast-growing cancer genetics testing and has strategic partnerships with oncologists and hospitals.
- Management aims to continue expanding the test menu and achieving operating leverage to accelerate cash flow and earnings.
20160126 smb m dx health jan groen
MDxHealth provides molecular diagnostic tests to improve diagnosis and treatment decisions for urological cancers like prostate and bladder cancer. Their lead product is ConfirmMDx, which helps determine if a repeat biopsy is needed after an initial negative biopsy result. They are also launching SelectMDx, a urine-based test to improve patient selection for initial biopsies. Looking forward, they plan to expand their product portfolio and commercial footprint in the US and EU to address unmet needs in urological cancer testing and help reduce unnecessary invasive procedures.
NeoGenomics, Inc. Company Overview Presentation 2013_10_01
NeoGenomics, Inc. Company Overview Presentation 2013_10_01NeoGenomics Laboratory | Cancer Diagnostics
This presentation provides an overview of NeoGenomics, a cancer genetics testing company. Key points include:
- NeoGenomics has experienced strong and consistent growth in revenue and test volume historically through strategic partnerships and an expanding test menu.
- The company focuses on fast turnaround times and exceptional client service to drive continued growth.
- Management aims to increase market share and profitability through expanding sales coverage, new test offerings like next generation sequencing, and potential M&A opportunities.
- NeoGenomics seeks to capitalize on favorable industry trends like an aging population, rise of personalized medicine, and consolidation in the cancer diagnostics field.Nobilis health ir_deck_nov final
- Nobilis Health Corp owns and operates ambulatory surgical centers and surgical hospitals across 7 states.
- They utilize a unique direct-to-patient marketing model to drive organic growth and capitalize on the trend of increased healthcare consumerism.
- For 2015, Nobilis reported revenue of $229.2 million and adjusted EBITDA of $42.1 million. They expect continued growth through organic expansion and acquisitions in a fragmented market.
VIATAR CTC SOLUTIONS
Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The Company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells (CTCs) from whole blood using label-free cross-flow filtration. It is designed to be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate, and gastric cancers. This proprietary technology also powers the Company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers, and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives. The Company’s liquid biopsy products are currently generating revenue, and sales are expected to increase in the coming quarters.
Viatar ctc-solutions-9-16-15
Viatar is a medtech company focused on developing products to treat cancer patients. Its lead product, the Viatar Therapeutic Oncopheresis System, removes circulating tumor cells from blood to improve cancer outcomes. Animal studies show removing CTCs can slow cancer progression and increase survival. The system may address a $1.5 billion market. Viatar is also developing liquid biopsy products to collect CTCs for cancer screening and research. The company expects to begin commercializing products in Europe in late 2016 and the US after additional clinical trials.
More Related Content
Similar to New Company for New Therapeutics for Prostate Cancer, New therapeutic approches for prostate cancer door Jack Schalken
SCIE Investor Presentation January 2017
This document discusses SpectraScience's optical biopsy technology platform and commercialization plans. The technology uses light to provide faster, non-invasive cancer detection compared to physical biopsies. Clinical studies show the technology exceeds accuracy criteria for detecting colon cancer. The company plans to commercialize the technology first in Europe, where distribution agreements are in place, to take advantage of single-payer healthcare systems and proven cost savings. Future indications for bladder, esophageal, and other cancers are also discussed.
2015 Investor Conference - Baxalta
The document outlines the strategic vision and priorities of Baxalta Incorporated, a $6 billion global biopharmaceutical company. It discusses plans to build three growing businesses in hematology, immunology, and oncology focused on orphan diseases. Baxalta aims to drive 6-8% annual sales growth through 20 new product launches by 2020, expanding its oncology business to $500 million plus in sales. The presentation highlights Baxalta's leadership team, global operations, robust pipeline, and financial outlook targeting high and sustainable margins through 2020.
2016 11 21 neo company overview presentation
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion that is growing due to cancer prevalence increasing with an aging population and more cancer tests through precision medicine.
- Recent financial performance shows year-over-year revenue growth of 142% and adjusted EBITDA growth of 224% for the first three quarters of 2016, which includes the effects of the Clarient acquisition.
Dendreon Strategic Analysis
Dendreon Corporation is developing novel immunotherapies to treat cancer. It has one product, Provenge, approved for late-stage prostate cancer which works by re-engaging the immune system. While showing promise, Provenge faces challenges of high costs, lengthy approval delays, and lawsuits seeking earlier access. Dendreon needs to diversify its pipeline and pursue financing to support clinical trials and market expansion.
Final_Medtronic+plc+ppt
Medtronic is a global leader in medical technology, services, and solutions, with $28.8 billion in annual revenue. It manufactures and markets device-based medical therapies for cardiac and vascular disease, spinal and orthopedic conditions, diabetes, and other chronic diseases. Some key points:
- Medtronic acquired Covidien in 2015 for $50 billion to expand its product portfolio and global reach. However, expenses increased greatly following the acquisition.
- Analysts have a average target price of $91.50 per share, citing Medtronic's leading position and innovation potential, though also noting increasing competition and pricing pressure.
- Using a DCF model, the analyst values Med
Dendreon Presentation
Dendreon Corporation is a biotechnology company focused on developing immunotherapies to treat cancer. It currently has one product, Provenge, approved for treating advanced prostate cancer. Provenge harnesses the power of the immune system by using a patient's own immune cells to fight cancer cells. Clinical trials showed Provenge increased survival rates by 22% in treated patients compared to the control group. However, Dendreon faces challenges of gaining FDA approval for additional indications and managing costs of manufacturing and distributing its complex cellular immunotherapy.
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
This document summarizes the 2015 annual meeting of Valeant Pharmaceuticals International, Inc. held on May 19, 2015 in Laval, Quebec, Canada. It introduces the board of directors and executive management in attendance. It reports that all proposed resolutions, including electing directors and ratifying the auditor, received over 90% shareholder approval. The document provides an overview of Valeant's business model, product portfolio, acquisition and R&D strategies, and highlights key pipeline and launch products. It concludes by emphasizing Valeant's track record of strong financial performance and shareholder returns.
NeoGenomics Laboratory Company Overview Presentation 01/20/2014
NeoGenomics Laboratory Company Overview Presentation 01/20/2014NeoGenomics Laboratory | Cancer Diagnostics
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experienceCrb Bio Ii Summary Nov2010 Eng
This document introduces a new €60 million venture capital fund called CRB Bio II that will invest in early-stage biotech companies. It will be managed by CRB Inverbío, a new venture capital firm created by the founding partners of Cross Road Biotech, a Spanish VC firm with experience investing in 11 biotech companies. The fund aims to generate high returns by leveraging the management team's expertise and network in the biotech industry in Spain.
NeoGenomics Laboratory Company Overview Presentation 01/09/2014
NeoGenomics Laboratory Company Overview Presentation 01/09/2014NeoGenomics Laboratory | Cancer Diagnostics
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experienceNeoGenomics Laboratory Company Overview Presentation 02/19/2014
NeoGenomics Laboratory Company Overview Presentation 02/19/2014NeoGenomics Laboratory | Cancer Diagnostics
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experienceCancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...NeoGenomics Laboratory | Cancer Diagnostics
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experienceNeoGenomics Company Overview 2.22.16
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
2014 03 11 neo company overview presentation
The presentation provides an overview of NeoGenomics, a cancer genetic testing company. It highlights the company's consistent historical growth in tests performed and revenue. The management team has significant experience in large cap clinical laboratories. The company aims to continue expanding its test menu and market share through new product development and partnerships within the fast-growing cancer genetic testing industry.
NeoGenomics Laboratory Company Overview 2014-03-11
This presentation provides an overview of NeoGenomics, a cancer genetic testing company. Key points include:
- NeoGenomics has experienced consistent historical growth in the number of cancer tests performed and annual revenue.
- The company focuses on fast-growing cancer genetics testing and has strategic partnerships with oncologists and hospitals.
- Management aims to continue expanding the test menu and achieving operating leverage to accelerate cash flow and earnings.
20160126 smb m dx health jan groen
MDxHealth provides molecular diagnostic tests to improve diagnosis and treatment decisions for urological cancers like prostate and bladder cancer. Their lead product is ConfirmMDx, which helps determine if a repeat biopsy is needed after an initial negative biopsy result. They are also launching SelectMDx, a urine-based test to improve patient selection for initial biopsies. Looking forward, they plan to expand their product portfolio and commercial footprint in the US and EU to address unmet needs in urological cancer testing and help reduce unnecessary invasive procedures.
NeoGenomics, Inc. Company Overview Presentation 2013_10_01
NeoGenomics, Inc. Company Overview Presentation 2013_10_01NeoGenomics Laboratory | Cancer Diagnostics
This presentation provides an overview of NeoGenomics, a cancer genetics testing company. Key points include:
- NeoGenomics has experienced strong and consistent growth in revenue and test volume historically through strategic partnerships and an expanding test menu.
- The company focuses on fast turnaround times and exceptional client service to drive continued growth.
- Management aims to increase market share and profitability through expanding sales coverage, new test offerings like next generation sequencing, and potential M&A opportunities.
- NeoGenomics seeks to capitalize on favorable industry trends like an aging population, rise of personalized medicine, and consolidation in the cancer diagnostics field.Nobilis health ir_deck_nov final
- Nobilis Health Corp owns and operates ambulatory surgical centers and surgical hospitals across 7 states.
- They utilize a unique direct-to-patient marketing model to drive organic growth and capitalize on the trend of increased healthcare consumerism.
- For 2015, Nobilis reported revenue of $229.2 million and adjusted EBITDA of $42.1 million. They expect continued growth through organic expansion and acquisitions in a fragmented market.
VIATAR CTC SOLUTIONS
Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The Company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells (CTCs) from whole blood using label-free cross-flow filtration. It is designed to be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate, and gastric cancers. This proprietary technology also powers the Company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers, and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives. The Company’s liquid biopsy products are currently generating revenue, and sales are expected to increase in the coming quarters.
Viatar ctc-solutions-9-16-15
Viatar is a medtech company focused on developing products to treat cancer patients. Its lead product, the Viatar Therapeutic Oncopheresis System, removes circulating tumor cells from blood to improve cancer outcomes. Animal studies show removing CTCs can slow cancer progression and increase survival. The system may address a $1.5 billion market. Viatar is also developing liquid biopsy products to collect CTCs for cancer screening and research. The company expects to begin commercializing products in Europe in late 2016 and the US after additional clinical trials.
Similar to New Company for New Therapeutics for Prostate Cancer, New therapeutic approches for prostate cancer door Jack Schalken (20)
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
Valeant Pharmaceuticals 2015 Annual Shareholders Meeting
NeoGenomics Laboratory Company Overview Presentation 01/20/2014
NeoGenomics Laboratory Company Overview Presentation 01/20/2014
NeoGenomics Laboratory Company Overview Presentation 01/09/2014
NeoGenomics Laboratory Company Overview Presentation 01/09/2014
NeoGenomics Laboratory Company Overview Presentation 02/19/2014
NeoGenomics Laboratory Company Overview Presentation 02/19/2014
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
NeoGenomics Laboratory Company Overview 2014-03-11
NeoGenomics Laboratory Company Overview 2014-03-11
NeoGenomics, Inc. Company Overview Presentation 2013_10_01
NeoGenomics, Inc. Company Overview Presentation 2013_10_01
More from Health Valley
HVE 2014 Pecha Kucha: Pieter van Gorp
Health and fitness apps and devices collect users' personal data, but it is unclear how user data is monetized and who earns from it. A proposed solution is a personal health record platform with an open app store that crowd-sources app development and takes a percentage of app store revenues, while providing platform-level privacy and easy data access. This could form the basis of a new business model for personal health and healthcare data.
HVE 2014 Pecha Kucha: Maarten Merckx
This document discusses using ELISA without washing steps by developing a switchable reporter enzyme system. It describes tuning a beta-lactamase enzyme and its inhibitor protein to have high affinity binding and then using this system for wash-free ELISA assays. The goal is to create assays that are faster and require less hands-on time by eliminating washing steps traditionally required in ELISA.
Health Valley Event 2014: Jan Raaijmakers, Universiteit Utrecht
Presentatie van Jan Raaijmakers (Universiteit Utrecht) op het Health Valley Event 2014 tijdens de sessie Personalized Medicine.
Health Valley Event 2014: Alain van Gool, Radboudumc
Presentatie van Alain van Gool (Radboudumc) op het Health Valley Event 2014 tijdens de sessie Personalised Medicine.
Health Valley Event 2014: Han van Krieken, Radboudumc
Presentatie van Han van Krieken (Radboudumc) op het Health Valley Event 2014 tijdens de sessie intergrale zorg.
Health Valley Event 2014: Chiel Bos, CPZ
Presentatie Chiel Bos (CPS) op het Health Valley Event 2014 tijdens de sessie intergrale zorg.
Health Valley 2014: Dick Herfst
Presentatie Dick Herfst (ZZG Zorggroep) op het Health Valley Event 2014 tijdens de sessie intergrale zorg
Health Valley 2014: Jack Schalken
Jack Schalken has co-founded two companies - NovioGendix in 2006 and Oncodrone in 2013 - to translate his translational research into clinical applications and products. As an "entrepreneurial scientist", he learned important lessons about negotiating terms with his academic institution, building a management team, securing financing, and acquiring business skills to successfully launch and grow these ventures. Both companies have worked to bridge the gap between research and clinical validation or product development for cancer diagnostics and therapeutics.
Health Valley Event 2014: Co Politiek, Aimpact
Presentatie van Co Politiek op het Health Valley Event 2014 tijdens de sessie e-health.
Health Valley Event 2014: Marieke Hettinga, Windesheim
Presentatie 'Succesvol ondernemen met e-health' van Marieke Hettinga (Windesheim) op het het Health Valley Event 2014 tijdens de sessie e-Health.
More from Health Valley (20)
Keynote Jorrit Ebben (Siza) "HV Afslag Twente" 20-11-2014
Keynote Jorrit Ebben (Siza) "HV Afslag Twente" 20-11-2014
Health Valley Event 2014: Anja Garritsen, Innatoss
Health Valley Event 2014: Anja Garritsen, Innatoss
Health Valley Event 2014: Jan Raaijmakers, Universiteit Utrecht
Health Valley Event 2014: Jan Raaijmakers, Universiteit Utrecht
Health Valley Event 2014: Alain van Gool, Radboudumc
Health Valley Event 2014: Alain van Gool, Radboudumc
Health Valley Event 2014: Han van Krieken, Radboudumc
Health Valley Event 2014: Han van Krieken, Radboudumc
Health Valley Event 2014: Marieke Hettinga, Windesheim
Health Valley Event 2014: Marieke Hettinga, Windesheim
New Company for New Therapeutics for Prostate Cancer, New therapeutic approches for prostate cancer door Jack Schalken
- 1. NEW THERAPEUTIC APPROACHES FOR PROSTATE CANCER
- 3. Result of long-standing collaboration
- 4. PRO-NET
Editor's Notes
- Aangeven dat PRIMA en PRO_net met zelfde partners is en consortium agreement leidend is voor op te richten BV Vraag commissie: Veel partijen betrokken bij HTS werk waardoor integratie `challenging`zal worden. Dus aangeven dat partijen al vele jaren met succes samenwerken en dat dat dus wel gaat lukken.